Friday, March 20, 2026 3/20/2026

Paracrine feedback by pancreatic delta cells to control glucagon and insulin release and manage diabetes

Award Number: R01DK110276
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2017
PERIOD OF PERFORMANCE END DATE: 03/31/2028

Group Awards By:

View Award Description

Paracrine feedback by pancreatic delta cells to control glucagon and insulin release and manage diabetes - Half of US adults have diabetes or pre-diabetes, illustrating a critical need for novel treatments. There is a fundamental gap in the understanding of how paracrine feedback in the islet controls insulin and glucagon. The long-term goal is to elucidate the (patho)physiological crosstalk within pancreatic islets in order to identify novel therapeutic targets. The overall objective in this application is to understand how endogenous SST inhibits Ca2+ and cAMP pathways in alpha and beta cells concurrently to balance inhibition of insulin and glucagon exocytosis. How a single inhibitory hormone can balance the inhibition of beta and alpha cells is a major and poorly understood aspect of islet physiology. The central hypothesis is that the pancreatic delta cell coordinates with beta cells to attenuate insulin and glucagon secretion by inhibiting Ca2+ and cAMP while concurrently remodeling the F-actin cytoskeleton to limit exocytosis. The rationale for the proposed research is that elucidating the mechanisms and circumstances of delta inhibition of alpha and beta cells would establish a better understanding of the physiological role of delta cells. This hypothesis will be tested in 3 specific aims. Aim 1 tests the hypothesis that beta and delta cells coordinate responses largely independently of gap junctions via the exchange of paracrine factors. Beta and delta cell calcium behavior will be quantified across hundreds of beta and delta cells in the same intact islets by GCaMP6. Dye injection experiments will determine if gap junctions can account for the coordinated delta and beta cell behavior. Aim 2 tests the hypothesis that endogenous delta cell feedback inhibition leads to robust intra-islet elevations of SST that coordinate alpha and beta cell behaviors via the combined inhibition of cAMP and Ca2+. Beta cells primarily respond to glucose with Ca2+. Insulin release is potentiated by cAMP. Ca2+ and cAMP will be quantified across hundreds of alpha and beta cells expressing biosensors for Ca2+ and cAMP in islets with or without SST. We will quantify local SST release via unique Sstr2 and Sstr3 (ant)agonists to determine the relative importance of cilia SSTR3 and cell-surface Sstr2. Aim 3 tests the hypothesis that activation of SSTR2 and SSTR3 on alpha and beta cells differentially inhibits exocytosis by remodeling the cortical F-actin network by activating RhoA GTPase. F-actin remodeling will be tested directly using FRET biosensors for RhoA expressed by stable MIN6 cells and primary islets in response to SST, by measuring dynamic remodeling of cortical F-actin via LifeAct, and by quantifying transcriptional changes to stimulation of primary alpha and beta cells with SSTR2 and SSTR3-selective agonists. The research is conceptually and technically innovative, in the applicants' opinion, as it evaluates the important physiological role of delta cells within intact islets in attenuating alpha and beta cell activity. It attains this by applying new technologies to overcome the hurdles that have previously precluded such studies. This is significant because delta cell control over glucagon and insulin secretion has broad translational importance towards novel strategies to curb the diabetes epidemic in the US.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $482,979 )
2026	2026	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	9	3/9/2026	NON-COMPETING CONTINUATION	$482,979
														Subtotal = $482,979

Issue Date FY: 2025 ( Subtotal = $482,979 )
2025	2025	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	8	4/17/2025	NON-COMPETING CONTINUATION	$482,979
														Subtotal = $482,979

Issue Date FY: 2024 ( Subtotal = $462,960 )
2024	2024	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	7	5/23/2024	NON-COMPETING CONTINUATION	$462,960
2024	2021	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	5	5/8/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $462,960

Issue Date FY: 2023 ( Subtotal = $479,698 )
2023	2023	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	6	2/22/2023	COMPETING CONTINUATION	$479,698
2023	2021	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	5	2/21/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $479,698

Issue Date FY: 2021 ( Subtotal = $392,500 )
2021	2021	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	5	5/25/2021	NON-COMPETING CONTINUATION	$392,500
														Subtotal = $392,500

Issue Date FY: 2020 ( Subtotal = $392,500 )
2020	2020	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	6/8/2020	NON-COMPETING CONTINUATION	$392,500
														Subtotal = $392,500

Issue Date FY: 2019 ( Subtotal = $392,500 )
2019	2019	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	7/8/2019	NON-COMPETING CONTINUATION	$392,500
														Subtotal = $392,500

Issue Date FY: 2018 ( Subtotal = $392,500 )
2018	2018	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	6/4/2018	NON-COMPETING CONTINUATION	$392,500
														Subtotal = $392,500

Issue Date FY: 2017 ( Subtotal = $392,500 )
2017	2017	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	6/15/2017	NEW	$392,500
														Subtotal = $392,500

Grand Total All Awards = $3,871,116

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Paracrine feedback by pancreatic delta cells to control glucagon and insulin release and manage diabetes

Award Number: R01DK110276

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2017

PERIOD OF PERFORMANCE END DATE: 03/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer